A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
Phase 3
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00038636
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
UCSD Treatment Center
🇺🇸San Diego, California, United States
Johns Hopkins Hospital
🇺🇸Baltimore, Maryland, United States
The University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Hopital Pitie-Salpetriere
🇫🇷Paris, France
Hospital Europeen Georges Pompidou
🇫🇷Paris, France
Hospital Clinico de Barcelona
🇪🇸Barcelona, Spain
Ciutat Sanitaria de Bellvitge
🇪🇸Barcelona, Spain
UCSD Treatment Center🇺🇸San Diego, California, United States